Alzheimer disease: Clinical use of cholinergic drugs in Alzheimer disease

Nature Reviews Neurology

Volumn 6, Issue 8, 2010, Pages 418-420

  Desmarais, Julie Eve ^a   Gauthier, Serge ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CETIRIZINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; HYDROXYZINE; LORATADINE; SEROTONIN UPTAKE INHIBITOR;

ALZHEIMER DISEASE; ANXIETY; ANXIETY DISORDER; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRACTURE; FRAIL ELDERLY; HUMAN; MENTAL DETERIORATION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RESTLESSNESS; SHORT SURVEY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ALZHEIMER DISEASE; CHOLINERGIC AGENTS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 77956258154     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.105     Document Type: Short Survey

References (5)

1. Gardette, V. et al. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2?year prospective, multicentre, cohort study. CNS Drugs 24, 431-442 (2010).
2. Burns, A. et al. Clinical practice with anti? dementia drugs: a consensus statement from British Association for Psychopharmacology. J. Psychopharmacol. 20, 732-755 (2006).
3. Rodda, J. & walker, Z. Ten years of cholinesterase inhibitors. Int. J. Geriatr. Psychiatry 24, 437-442 (2009).
4. Herrmann, N. et al. A population-based study of cholinesterase inhibitor use for dementia. J. Am. Geriatr. Soc. 55, 1517-1523 (2007).
5. Kogut, S. J., el-Maouche, D. & Abughosh, S. M. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy 25, 1729-1735 (2005).